Quantcast
Last updated on April 19, 2014 at 1:20 EDT

Latest Jazz Pharmaceuticals plc Stories

2013-05-14 00:21:25

DUBLIN, May 13, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will participate in three upcoming investor events. A live audio webcast of each presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. The events, presentation times and speakers include: UBS Global Healthcare Conference in New York, NY on Tuesday, May 21, 2013 at 9:30 a.m. EDT/2:30 p.m. IST. Kathryn E. Falberg,...

2013-05-07 16:29:12

Company Reports Total Revenues of $196 Million Driven by Record Net Sales of Xyrem and Erwinaze DUBLIN, May 7, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter ended March 31, 2013, updated 2013 financial guidance and key additions to its board of directors. "During the first quarter, we continued to deliver strong top and bottom line growth fueled by growing sales of Xyrem and Erwinaze," said Bruce Cozadd,...

2013-04-23 16:25:33

DUBLIN, April 23, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its first quarter 2013 financial results on Tuesday, May 7, 2013, after the close of the financial markets. The announcement will be followed by a conference call and live webcast at 4:30 p.m. EDT/9:30 p.m. IST. During the call, company management will provide a business and financial update and review its first quarter 2013 results. A live webcast of the presentation...

2013-03-05 08:30:48

DUBLIN, March 5, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the pricing of a previously announced underwritten public offering of 5,375,000 of its ordinary shares held by certain of its existing shareholders, offered at a price to the public of $58.50 per share. Jazz Pharmaceuticals will not receive any proceeds from the sale of ordinary shares by the selling shareholders in the offering, and its total number of ordinary shares outstanding will not change as...

2013-03-04 16:26:13

DUBLIN, March 4, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced an underwritten public offering of 5,375,000 of its ordinary shares held by certain of its existing shareholders. Jazz Pharmaceuticals will not receive any proceeds from the sale of ordinary shares by the selling shareholders in the offering, and its total number of ordinary shares outstanding will not change as a result of the offering. Barclays Capital Inc. is acting as sole...

2013-02-27 08:30:31

DUBLIN, Feb. 27, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that the company will participate in two upcoming investor conferences. A live webcast of each presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. The conferences, presentation times and speakers include: Cowen and Company 33rd Annual Healthcare Conference in Boston, MA on Wednesday, March 6, 2013 at 8:40 a.m. EST/1:40 p.m....

2013-02-26 16:27:29

- Record Total Revenues of $586 Million in 2012 - DUBLIN, Feb. 26, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter ended December 31, 2012. "2012 was a transformational year, with the acquisitions of Azur Pharma and EUSA Pharma expanding our business and allowing us to improve more patients' lives," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals plc. "In 2013, we...

2013-02-11 16:27:43

DUBLIN, Feb. 11, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will host a conference call and live webcast on Tuesday, February 26, 2013 at 4:30 p.m. EST/9:30 p.m. GMT. During the call, company management will provide a business and financial update and review its 2012 fourth quarter and full year financial results. A live webcast of the presentation may be accessed from the Investors & Media section of the Jazz Pharmaceuticals website at...

2013-01-02 16:22:38

DUBLIN, Jan. 2, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that the company will webcast its presentation at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 8, 2013. The webcast is scheduled to begin at 10:00 a.m. PST (6:00 p.m. GMT). Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals, will present an overview of the company and provide a business and financial update. The webcast can be...

2012-12-04 16:26:52

DUBLIN, Dec. 4, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the United States Patent and Trademark Office has issued a patent related to the use of Xyrem® (sodium oxybate) oral solution for the treatment of narcolepsy, titled "Microbiologically Sound and Stable Solutions of Gamma-Hydroxybutyrate Salt for the Treatment of Narcolepsy." The new patent, number 8,324,275, will be submitted for listing in the FDA's Approved Drug Products With Therapeutic...